| Literature DB >> 35115886 |
Iswandi Darwis1,2, Hidayat Hidayat3, Gusti Ngurah P Pradnya Wisnu2, Sekar Mentari2.
Abstract
BACKGROUND: Diabetic foot infection (DFI) is a serious complication of diabetes mellitus and identification of the causative bacteria is an essential step in selecting the appropriate antibiotic therapy. This study aimed to evaluate the bacterial pattern and antibiotic susceptibility of the bacteria causing DFI in Lampung Province in Indonesia.Entities:
Keywords: antibiotic treatment; diabetic foot; infection; microbiology; ulcer
Year: 2021 PMID: 35115886 PMCID: PMC8793971 DOI: 10.21315/mjms2021.28.5.4
Source DB: PubMed Journal: Malays J Med Sci ISSN: 1394-195X
Characteristics of the study subjects
| Characteristics | |
|---|---|
| Ages (years old) | 53.9 (9.2) |
| Sex | |
| Male | 57 (43.5%) |
| Female | 74 (56.5%) |
| Length of stay(days) | 10.7 (5.9) |
| Mortality | 18 (13.7%) |
|
| |
|
| |
|
| |
| Haemoglobin (g/dL) | 9.3 (2.0) |
| WBC (/mm3) | 19084.4 (7821.3) |
| Platelet (/mm3) | 422133 (170205) |
| Random blood glucose (mg/dL) | 265 (123.2) |
Bacteria isolated from a DFI
| Bacteria | ( | Percentage (%) |
|---|---|---|
| Gram-negative | ||
| 33 | 25.2 | |
| 27 | 20.6 | |
| 21 | 16.0 | |
| 17 | 12.9 | |
| 7 | 5.3 | |
| 2 | 1.5 | |
| 2 | 1.5 | |
| 2 | 1.5 | |
| 1 | 0.7 | |
| 1 | 0.7 | |
| 1 | 0.7 | |
| Gram-positive | ||
| 14 | 10.7 | |
| 3 | 2.3 | |
Mortality and length of hospital stay among patients with DFI
| Nature of infection | |||
|---|---|---|---|
|
| |||
| Monomicrobial | Polymicrobial | ||
| In-hospital mortality | 16 (14.4%) | 2 (20%) | 0.643 |
| Length of hospital stay (days) | 11.5 (7) | 10 (8) | 0.204 |
Notes: Reported counts (proportions) for categorical variables and median (interquartile range) for continuous variables;
Fisher’s exact test was applied;
Mann-Whitney-U test was applied
Antibiotic susceptibility pattern of Gram-negative bacteria isolated from a DFI
| Antibiotics | Proportion of susceptibility (%) |
|---|---|
| Amikacin | 95.5 |
| Meropenem | 92.6 |
| Sulbactam/Cefoperazone | 90.6 |
| Ertapenem | 75.9 |
| Netilmicin | 71.9 |
| Piperacillin/Tazobactam | 57.6 |
| Trimethoprim/Sulfamethoxazole | 57.1 |
| Amoxicillin/Clavulanic | 56.0 |
| Piperacillin/Tazobactam | 54.6 |
| Gentamicin | 53.0 |
| Ciprofloxacin | 52.2 |
| Cefepime | 51.5 |
| Clindamycin | 50.0 |
| Sulbactam/Ampicillin | 43.8 |
| Ceftazidime | 43.1 |
| Cefoperazone | 39.6 |
| Ceftriaxone | 34.1 |
| Cefotaxime | 30.9 |
| Chloramphenicol | 28.3 |
| Tetracycline | 22.6 |
| Cefixime | 13.9 |
| Ampicillin | 13.4 |
| Penicillin | 11.1 |
| Erythromycin | 10.7 |
| Amoxicillin | 10.7 |
| Cefadroxil | 10.6 |
Antibiotic susceptibility pattern of Gram-positive bacteria isolated from a DFI
| Antibiotics | Proportion of susceptibility (%) |
|---|---|
| Meropenem | 92.9 |
| Sulbactam/Cefoperazone | 86.7 |
| Amikacin | 80.0 |
| Trimethoprim/Sulfamethoxazole | 66.7 |
| Sulbactam/Ampicillin | 66.7 |
| Amoxicillin/Clavulanic | 53.8 |
| Ceftriaxone | 50.0 |
| Netilmicin | 50.0 |
| Ciprofloxacin | 37.5 |
| Gentamicin | 33.3 |
| Chloramphenicol | 30.8 |
| Amoxicillin | 23.1 |
| Cefadroxil | 21.4 |
| Cefotaxime | 11.1 |
| Cefoperazone | 10.0 |
| Tetracycline | 6.7 |
| Cefixime | 0 |
| Clindamycin | 0 |
| Erythromycin | 0 |
| Penicillin | 0 |
| Ampicillin | 0 |
Antibiotic susceptibility pattern of the five most commonly isolated bacteria from a DFI
| Bacteria | Antibiotics | Proportion of susceptibility (%) |
|---|---|---|
| Amikacin | 100 | |
| Meropenem | 100 | |
| Sulbactam/Cefoperazone | 87 | |
| Trimethoprim/ Sulfamethoxazole | 83.3 | |
| Piperacillin/Tazobactam | 80 | |
| Ciprofloxacin | 62.5 | |
| Netilmicin | 60 | |
| Tigecycline | 60 | |
| Amoxicillin/Clavulanic | 52.2 | |
| Ceftazidime | 50 | |
| Amikacin | 100 | |
| Sulbactam/Cefoperazone | 100 | |
| Meropenem | 91.7 | |
| Tigecycline | 88.9 | |
| Netilmicin | 71.4 | |
| Ertapenem | 66.7 | |
| Amoxicillin/Clavulanic | 60 | |
| Gentamicin | 47.8 | |
| Ceftriaxone | 40 | |
| Trimethoprim/Sulfamethoxazole | 40 | |
| Meropenem | 100 | |
| Sulbactam/Cefoperazone | 100 | |
| Amikacin | 80.9 | |
| Ertapenem | 75 | |
| Piperacillin/Tazobactam | 71.4 | |
| Ciprofloxacin | 63.6 | |
| Cefepime | 50 | |
| Gentamicin | 50 | |
| Sulbactam/Ampicillin | 50 | |
| Trimethoprim/Sulfamethoxazole | 50 | |
| Ceftazidime | 46.2 | |
| Amoxicillin/Clavulanic | 45.4 | |
| Cefoperazone | 45.4 | |
| Amikacin | 100 | |
| Meropenem | 100 | |
| Sulbactam/Cefoperazone | 88.9 | |
| Cefepime | 83.3 | |
| Netilmicin | 83.3 | |
| Gentamicin | 68.7 | |
| Piperacillin/Tazobactam | 66.7 | |
| Amoxicillin/Clavulanic | 50 | |
| Trimethoprim/Sulfamethoxazole | 50 | |
| Ciprofloxacin | 42.9 | |
| Sulbactam/Ampicillin | 42.9 | |
| Ceftazidime | 41.7 | |
| Sulbactam/Cefoperazone | 91.7 | |
| Meropenem | 90.9 | |
| Amikacin | 75 | |
| Trimethoprim/Sulfamethoxazole | 66.7 | |
| Sulbactam/Ampicillin | 66.7 | |
| Ceftriaxone | 50 | |
| Amoxicillin/Clavulanic | 50 | |
| Netilmicin | 50 | |
| Chloramphenicol | 40 |